title: Chemotherapy and endocrine function in lung cancer.
abstract: To investigate whether cyclic chemotherapy for lung cancer influenced endocrine function, we monitored thyroxine, cortisol, testosterone, sex hormone binding globulin (SHBG), estradiol, FSH, LH, and transcortin every three weeks in 12 male patients. Treatment regimens consisted of cisplatin and etoposide in 9 patients, or vincristine, doxorubicin, and cyclophosphamide in 3 patients. SHBG and FSH level were significantly elevated after 6 to 9 weeks of therapy, whereas the other variables were unchanged. The results suggest that the therapy induces endocrine gonadal dysfunction. The increments in SHBG levels reflect a considerable fall in free testosterone, and may effect alterations in total androgen/estrogen ratios. The mechanism underlying the increased SHBG levels is unknown.
authors.affiliation: Department of Chest Medicine, University Hospital of Tromsø, Norway.
authors.forename: U
authors.initials: U
authors.lastname: Aasebø
authors.forename: L
authors.initials: L
authors.lastname: Slørdal
authors.forename: S
authors.initials: S
authors.lastname: Aanderud
authors.forename: A
authors.initials: A
authors.lastname: Aakvaag
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004702:Endocrine Glands / Q000187:drug effects* / Q000503:physiopathology; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013739:Testosterone / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone